Saffron Walden, United Kingdom

Emanuela Gancia

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Karuna Therapeutics, Inc.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Emanuela Gancia. Retrieved from https://idiyas.com/inventor/emanuela-gancia-cb979ds9

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Emanuela Gancia: Innovator in Pharmaceutical Compounds

Introduction

Emanuela Gancia is a notable inventor based in Saffron Walden, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address medical conditions.

Latest Patents

Emanuela Gancia holds a patent for "Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions." This invention provides substituted tetrahydropyrrolo-pyridinone compounds, pharmaceutical compositions, and their application in treating muscarinic acetylcholine receptor mediated disorders. His innovative work has the potential to impact various therapeutic areas.

Career Highlights

Gancia is currently associated with Karuna Therapeutics, Inc., where he continues to advance his research and development efforts. His expertise in pharmaceutical sciences has positioned him as a valuable asset in the industry.

Collaborations

Emanuela has collaborated with notable colleagues, including Kevin Matthew Gardinier and James Edmund Audia. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Emanuela Gancia's contributions to pharmaceutical innovations exemplify the impact of dedicated inventors in advancing medical science. His work continues to pave the way for new treatments and therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…